The Post-Marketing Safety and Immunogenicity Research of Speeda® Rabies Vaccine for Human Use

Inclusion Criteria: * Parent/legal acceptable representatives of children or the adult participants are willing and able to understand the protocol requirements and provide informed consent signed * Participant is considered to be in good health including the body and mental status on the basis of reported medical history and limited physical examination and live in local ≥ 12 months * Participant body temperature ≤ 37.0℃ * Participant without preventive inoculation of rabies vaccine(only limited in immunogenicity subgroup) Exclusion Criteria: * Three-level exposure * Known allergy to any constituent of the vaccine * Reported the history of allergies, convulsions, epilepsy, mental illness and brain disease and clear serious systemic reaction * Known bleeding disorder or suspected impairment of immunologic function, or receipt of immunosuppressive therapy or immunoglobulin since birth * Participation in any other interventional clinical trial * An acute illness with or without fever (temperature \> 37.0℃) in the latest week preceding enrollment in the trial * Inoculated other vaccines, immunoglobulin or investigational drugs within 4 weeks prior to participation in the study * Reported clearly the infection of the upper respiratory tract with 6 months Clinical Manifestation of Metabolic, blood system, lungs, heart, the gastrointestinal tract, nervous system, kidneys, urinary system, endocrine, liver disease or malignant tumor * Any condition which, in the opinion of the investigator, would pose a health risk to the subject or interfere with the vaccine